HK1091132A1 - 抗- 抗體及其用途 - Google Patents
抗- 抗體及其用途Info
- Publication number
- HK1091132A1 HK1091132A1 HK06111884.0A HK06111884A HK1091132A1 HK 1091132 A1 HK1091132 A1 HK 1091132A1 HK 06111884 A HK06111884 A HK 06111884A HK 1091132 A1 HK1091132 A1 HK 1091132A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42433202P | 2002-11-07 | 2002-11-07 | |
PCT/US2003/032737 WO2004043344A2 (en) | 2002-11-07 | 2003-11-05 | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1091132A1 true HK1091132A1 (zh) | 2007-01-12 |
Family
ID=32312793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06111884.0A HK1091132A1 (zh) | 2002-11-07 | 2006-10-27 | 抗- 抗體及其用途 |
Country Status (25)
Country | Link |
---|---|
US (10) | US7557189B2 (zh) |
EP (1) | EP1578446B1 (zh) |
JP (1) | JP5354835B2 (zh) |
KR (1) | KR20050059332A (zh) |
CN (2) | CN1795009B (zh) |
AU (1) | AU2003285878B2 (zh) |
BR (1) | BR0316101A (zh) |
CA (1) | CA2504818C (zh) |
CO (1) | CO5580797A2 (zh) |
CR (1) | CR7853A (zh) |
CY (1) | CY1116406T1 (zh) |
DK (1) | DK1578446T3 (zh) |
EA (1) | EA010570B1 (zh) |
EC (1) | ECSP055831A (zh) |
ES (1) | ES2539627T3 (zh) |
HK (1) | HK1091132A1 (zh) |
HU (1) | HUE026914T2 (zh) |
IL (2) | IL168295A (zh) |
MX (1) | MXPA05004712A (zh) |
NO (1) | NO338498B1 (zh) |
NZ (1) | NZ539395A (zh) |
PT (1) | PT1578446E (zh) |
SI (1) | SI1578446T1 (zh) |
WO (1) | WO2004043344A2 (zh) |
ZA (1) | ZA200503075B (zh) |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1578446T3 (en) * | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
CA2579523C (en) | 2004-10-12 | 2016-04-12 | Crucell Holland B.V. | Atad3a-binding molecules for treatment, detection and prevention of cancer |
EP2468304A3 (en) | 2005-02-11 | 2012-09-26 | ImmunoGen, Inc. | Process for preparing stable drug conjugates |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
CA2893252C (en) | 2005-08-24 | 2018-05-29 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
GB0521991D0 (en) * | 2005-10-28 | 2005-12-07 | Univ Dundee | Siglec-9 binding agents |
EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
KR101528939B1 (ko) | 2006-07-18 | 2015-06-15 | 사노피 | 암 치료를 위한 epha2에 대한 길항제 항체 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
CA2667808A1 (en) * | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
DK2155248T3 (en) | 2007-04-12 | 2015-09-14 | Brigham & Womens Hospital | Targeting abcb5 for cancer therapy |
PT2019104E (pt) | 2007-07-19 | 2013-12-03 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
CN104524592B (zh) | 2008-04-30 | 2018-06-05 | 伊缪诺金公司 | 交联剂和它们的用途 |
DK2421898T3 (en) | 2009-04-20 | 2016-05-30 | Oxford Biotherapeutics Ltd | Cadherin-17 SPECIFIC ANTIBODIES |
KR101947176B1 (ko) | 2009-06-03 | 2019-02-12 | 이뮤노젠 아이엔씨 | 접합 방법 |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-gitr 항체 |
DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
KR20120080611A (ko) | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
US8524240B2 (en) | 2009-10-26 | 2013-09-03 | Djordje Atanackovic | Diagnosis and therapy of hematological malignancies |
IN2012DN03824A (zh) | 2009-10-30 | 2015-08-28 | Merck Sharp & Dohme | |
US20120282274A1 (en) * | 2009-11-20 | 2012-11-08 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment |
IL290617B2 (en) | 2010-02-24 | 2023-11-01 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
AU2011221553B2 (en) * | 2010-03-04 | 2016-05-26 | Vet Therapeutics Inc. | Monoclonal antibodies directed to CD20 |
AU2011223547B2 (en) | 2010-03-04 | 2016-05-05 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD52 |
US9616120B2 (en) * | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
US20130259878A1 (en) * | 2010-10-20 | 2013-10-03 | Oxford Biotherapeutics Ltd | Antibodies |
WO2012074097A1 (ja) * | 2010-12-03 | 2012-06-07 | 協和発酵キリン株式会社 | 抗cd33抗体 |
EP2487242A1 (en) | 2011-02-09 | 2012-08-15 | Ruprecht-Karls-Universität Heidelberg | B-type plexin antagonists and uses thereof |
SG191965A1 (en) | 2011-02-15 | 2013-08-30 | Immunogen Inc | Methods of preparation of conjugates |
CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
EP2691155B1 (en) | 2011-03-29 | 2018-11-14 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
AU2012272930B2 (en) | 2011-06-21 | 2015-06-11 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
AU2012340766B2 (en) | 2011-11-23 | 2018-05-10 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
CN102768283B (zh) * | 2012-07-23 | 2015-03-04 | 北京大学人民医院 | 一种检测或辅助检测髓系白血病细胞分化阶段的试剂盒 |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
KR20200079565A (ko) | 2012-08-31 | 2020-07-03 | 이뮤노젠 아이엔씨 | 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트 |
US10035817B2 (en) | 2012-10-04 | 2018-07-31 | Immunogen, Inc. | Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane |
ME03486B (me) | 2012-10-12 | 2020-01-20 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
EP2961435B1 (en) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
BR112015021965B1 (pt) | 2013-03-13 | 2022-05-03 | Medimmune Limited | Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos |
EP2968596B1 (en) | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US20160031887A1 (en) | 2013-03-13 | 2016-02-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6673200B2 (ja) | 2013-07-05 | 2020-03-25 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 骨髄異形成症候群(mds)を治療するための可溶性cd33 |
WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
WO2015089344A1 (en) * | 2013-12-13 | 2015-06-18 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
EP3082874A2 (en) * | 2013-12-16 | 2016-10-26 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
WO2015150526A2 (en) * | 2014-04-03 | 2015-10-08 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
CN106794129B (zh) | 2014-04-08 | 2020-05-12 | 波士顿制药有限公司 | 对il-21具有特异性的结合分子及其用途 |
KR20160143808A (ko) | 2014-04-11 | 2016-12-14 | 메디뮨 엘엘씨 | 이중특이적 her2 항체 |
SG11201609357PA (en) * | 2014-05-20 | 2016-12-29 | Immunogen Inc | Methods for characterizing and treating acute myeloid leukemia |
ES2805475T3 (es) * | 2014-07-21 | 2021-02-12 | Novartis Ag | Tratamiento del cáncer utilizando un receptor antigénico quimérico de CD33 |
MA40539A (fr) | 2014-09-02 | 2016-03-10 | Immunogen Inc | Procédés de formulation de compositions de conjugués anticorps-médicaments |
TWI757759B (zh) | 2014-09-03 | 2022-03-11 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
TW201613930A (en) | 2014-09-03 | 2016-04-16 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9867831B2 (en) * | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
LT3590962T (lt) * | 2014-10-23 | 2021-12-27 | Singh Molecular Medicine, Llc | Vieno domeno antikūnai, nukreipti prieš viduląstelinius antigenus |
JP6755866B2 (ja) | 2014-11-10 | 2020-09-16 | メディミューン リミテッド | Cd73特異的結合分子及びその使用 |
US20160129108A1 (en) | 2014-11-11 | 2016-05-12 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and uses thereof |
KR20170088905A (ko) | 2014-11-19 | 2017-08-02 | 이뮤노젠 아이엔씨 | 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정 |
BR112017011749A2 (pt) * | 2014-12-04 | 2018-05-15 | Janssen Biotech Inc | anticorpos anti-cd38 para o tratamento de leucemia mieloide aguda |
GB201501004D0 (en) | 2015-01-21 | 2015-03-04 | Cancer Rec Tech Ltd | Inhibitors |
CN107438618A (zh) | 2015-01-26 | 2017-12-05 | 塞勒克提斯公司 | 赋予结合至cd123的嵌合抗原受体用于治疗复发性/难治性急性骨髓性淋巴瘤或母细胞性浆细胞样树突状细胞肿瘤的t细胞受体敲除的工程化免疫细胞 |
CA2971288A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
CN114652827A (zh) | 2015-05-29 | 2022-06-24 | 安普希韦纳治疗公司 | 双特异性cd33和cd3结合蛋白质的使用方法 |
AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
US11174313B2 (en) | 2015-06-12 | 2021-11-16 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
RS61452B9 (sr) | 2015-06-29 | 2021-12-31 | Immunogen Inc | Anti-cd123 antitela i njihovi konjugati i derivati |
CA2988806A1 (en) | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Conjugates of cysteine engineered antibodies |
HUE050312T2 (hu) | 2015-11-10 | 2020-11-30 | Medimmune Llc | ASCT2-RE specifikus kötõmolekulák és alkalmazásaik |
CA3003482A1 (en) | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
WO2017091745A1 (en) | 2015-11-25 | 2017-06-01 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
MA47022A (fr) | 2016-02-05 | 2018-12-12 | Immunogen Inc | Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique |
KR20230152153A (ko) | 2016-03-10 | 2023-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
CA3017776A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
JP6843891B2 (ja) | 2016-06-02 | 2021-03-17 | アッヴィ・インコーポレイテッド | グルココルチコイド受容体アゴニスト及びこのイムノコンジュゲート |
US11110179B2 (en) | 2016-06-03 | 2021-09-07 | Seagen Inc. | Combination of CD33 antibody drug conjugates with chemotherapeutic agents |
US11191771B2 (en) | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
BR112019005449A2 (pt) * | 2016-09-20 | 2019-10-01 | Aronora Inc | anticorpos inovadores contra fator xi e usos dos mesmos |
CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
US20200261470A1 (en) | 2016-11-02 | 2020-08-20 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
CR20190297A (es) | 2016-11-23 | 2019-11-01 | Bioverativ Therapeutics Inc | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x |
WO2018098258A2 (en) | 2016-11-23 | 2018-05-31 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
AU2018229277A1 (en) | 2017-02-28 | 2019-10-10 | Immunogen, Inc. | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
TW201839001A (zh) | 2017-04-20 | 2018-11-01 | 美商伊繆諾金公司 | 細胞毒性苯并二氮平衍生物及其綴合物 |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
JP2020519640A (ja) * | 2017-05-17 | 2020-07-02 | イミュノジェン, インコーポレイテッド | 抗cd33イムノコンジュゲート投与計画 |
CR20190486A (es) | 2017-08-03 | 2020-02-10 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
BR112020004307A2 (pt) | 2017-09-20 | 2020-11-10 | Ph Pharma Co., Ltd. | análogos de tailanestatina |
CN117065043A (zh) | 2017-09-22 | 2023-11-17 | 伊缪诺金公司 | 防止免疫结合物中的甲硫氨酸氧化的方法 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
TW201922294A (zh) | 2017-10-31 | 2019-06-16 | 美商伊繆諾金公司 | 抗體-藥物結合物與阿糖胞苷之組合治療 |
US11793885B2 (en) | 2017-12-28 | 2023-10-24 | Immunogen, Inc. | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders |
SG11202007702UA (en) | 2018-02-14 | 2020-09-29 | Viela Bio Inc | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
KR20200131846A (ko) * | 2018-03-14 | 2020-11-24 | 메모리얼 슬로안 케터링 캔서 센터 | 항-폴리시알산 항체 및 그 용도 |
WO2019222130A1 (en) | 2018-05-15 | 2019-11-21 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and flt3 inhibitors |
AU2019275076A1 (en) * | 2018-05-23 | 2020-11-26 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
EP3796942A1 (en) | 2018-05-23 | 2021-03-31 | ADC Therapeutics SA | Molecular adjuvant |
JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
BR112020025048A2 (pt) | 2018-06-13 | 2021-04-06 | Novartis Ag | Receptores de antígeno quimérico de bcma e usos dos mesmos |
JP2021535140A (ja) * | 2018-08-28 | 2021-12-16 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 抗cd3抗体葉酸生物複合体およびその使用 |
CN113801229A (zh) * | 2018-08-31 | 2021-12-17 | 艾利妥 | 抗cd33抗体及其使用方法 |
EP3849565A4 (en) * | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS |
US20210292413A1 (en) * | 2018-09-25 | 2021-09-23 | Academia Sinica | Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof |
MX2021003554A (es) | 2018-09-25 | 2021-05-27 | Harpoon Therapeutics Inc | Proteinas de union a dll3 y metodos de uso. |
US20210324076A1 (en) * | 2018-10-12 | 2021-10-21 | Amphivena Therapeutics Inc | Cd33×cd3 binding proteins for treating inflammatory conditions and diseases |
AU2019377892A1 (en) * | 2018-11-07 | 2021-05-13 | Crispr Therapeutics Ag | Anti-CD33 immune cell cancer therapy |
US20220332800A1 (en) | 2018-11-20 | 2022-10-20 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
AU2020240310A1 (en) | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
KR20220010481A (ko) | 2019-03-29 | 2022-01-25 | 이뮤노젠 아이엔씨 | 비정상 세포 성장의 억제 또는 증식성 질환의 치료를 위한 세포독성 비스-벤조디아제핀 유도체 및 세포결합제와 이의 접합체 |
JP2022529854A (ja) | 2019-04-26 | 2022-06-24 | イミュノジェン・インコーポレーテッド | カンプトテシン誘導体 |
AR122270A1 (es) | 2019-05-20 | 2022-08-31 | Novartis Ag | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
CA3149683A1 (en) * | 2019-06-26 | 2020-12-30 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibodies for treating cancer |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
EP4247957A1 (en) | 2019-11-22 | 2023-09-27 | MedImmune Limited | Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation |
EP4084821A2 (en) | 2020-01-03 | 2022-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
EP4211166A1 (en) | 2020-09-11 | 2023-07-19 | MedImmune Limited | Therapeutic b7-h4 binding molecules |
EP4211663A2 (en) | 2020-09-12 | 2023-07-19 | MedImmune Limited | A scoring method for an anti-b7h4 antibody-drug conjugate therapy |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
EP4251209A1 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
US20240115607A1 (en) | 2021-01-26 | 2024-04-11 | Cytocares (Shanghai) Inc. | Chimeric antigen receptor (car) constructs and nk cells expressing car constructs |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
CA3212630A1 (en) | 2021-03-18 | 2022-09-22 | Medimmune Limited | Therapeutic binding molecules |
EP4337689A1 (en) | 2021-05-12 | 2024-03-20 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
ATE196477T1 (de) | 1989-12-14 | 2000-10-15 | Sloan Kettering Inst Cancer | Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon |
GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
US6417337B1 (en) | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
AU7921701A (en) * | 2000-08-08 | 2002-02-18 | Immunomedics Inc | Immunotherapy for chronic myelocytic leukemia |
DK1377314T3 (da) * | 2001-01-26 | 2011-12-12 | Inhibitex Inc | Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner |
DK1578446T3 (en) * | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
US20060233814A1 (en) * | 2005-04-15 | 2006-10-19 | Immunogen Inc. | Elimination of heterogeneous or mixed cell population in tumors |
MX2010013833A (es) * | 2008-06-16 | 2011-02-15 | Immunogen Inc | Nuevos efectos sinergisticos. |
SG11201609357PA (en) * | 2014-05-20 | 2016-12-29 | Immunogen Inc | Methods for characterizing and treating acute myeloid leukemia |
-
2003
- 2003-11-05 DK DK03779105.0T patent/DK1578446T3/en active
- 2003-11-05 EA EA200500778A patent/EA010570B1/ru not_active IP Right Cessation
- 2003-11-05 JP JP2004551530A patent/JP5354835B2/ja not_active Expired - Fee Related
- 2003-11-05 AU AU2003285878A patent/AU2003285878B2/en not_active Ceased
- 2003-11-05 WO PCT/US2003/032737 patent/WO2004043344A2/en active Application Filing
- 2003-11-05 MX MXPA05004712A patent/MXPA05004712A/es active IP Right Grant
- 2003-11-05 US US10/700,632 patent/US7557189B2/en not_active Expired - Fee Related
- 2003-11-05 KR KR1020057008083A patent/KR20050059332A/ko not_active Application Discontinuation
- 2003-11-05 PT PT37791050T patent/PT1578446E/pt unknown
- 2003-11-05 CA CA2504818A patent/CA2504818C/en not_active Expired - Fee Related
- 2003-11-05 CN CN200380102406.0A patent/CN1795009B/zh not_active Expired - Fee Related
- 2003-11-05 BR BR0316101-3A patent/BR0316101A/pt active Search and Examination
- 2003-11-05 HU HUE03779105A patent/HUE026914T2/en unknown
- 2003-11-05 ZA ZA200503075A patent/ZA200503075B/en unknown
- 2003-11-05 NZ NZ539395A patent/NZ539395A/en not_active IP Right Cessation
- 2003-11-05 ES ES03779105.0T patent/ES2539627T3/es not_active Expired - Lifetime
- 2003-11-05 CN CN201210362462.9A patent/CN102875680B/zh not_active Expired - Fee Related
- 2003-11-05 SI SI200332425T patent/SI1578446T1/sl unknown
- 2003-11-05 EP EP03779105.0A patent/EP1578446B1/en not_active Expired - Lifetime
-
2005
- 2005-04-14 IL IL168295A patent/IL168295A/en not_active IP Right Cessation
- 2005-05-20 CO CO05048853A patent/CO5580797A2/es not_active Application Discontinuation
- 2005-06-01 CR CR7853A patent/CR7853A/es not_active Application Discontinuation
- 2005-06-01 EC EC2005005831A patent/ECSP055831A/es unknown
- 2005-06-06 NO NO20052693A patent/NO338498B1/no not_active IP Right Cessation
-
2006
- 2006-04-10 US US11/400,241 patent/US7342110B2/en not_active Expired - Fee Related
- 2006-10-27 HK HK06111884.0A patent/HK1091132A1/zh not_active IP Right Cessation
-
2007
- 2007-12-20 US US11/961,256 patent/US20080167458A1/en not_active Abandoned
-
2009
- 2009-01-23 US US12/358,832 patent/US20090291090A1/en not_active Abandoned
- 2009-06-12 US US12/483,543 patent/US8119787B2/en not_active Expired - Fee Related
-
2011
- 2011-02-02 US US13/019,478 patent/US8337855B2/en not_active Expired - Fee Related
- 2011-02-23 IL IL211385A patent/IL211385A0/en unknown
-
2012
- 2012-11-19 US US13/680,614 patent/US8747851B2/en not_active Expired - Fee Related
-
2014
- 2014-04-10 US US14/249,602 patent/US9359442B2/en not_active Expired - Fee Related
-
2015
- 2015-06-19 CY CY20151100526T patent/CY1116406T1/el unknown
-
2016
- 2016-05-13 US US15/154,115 patent/US10000566B2/en not_active Expired - Fee Related
-
2018
- 2018-05-14 US US15/978,846 patent/US20180362646A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1091132A1 (zh) | 抗- 抗體及其用途 | |
IL225633A0 (en) | Antibodies against alpha v beta 6 and uses thereof | |
EP1551447A4 (en) | ANTI-ADDL ANTIBODIES AND USES THEREOF | |
EP1539941A4 (en) | ADZYMES AND THEIR USES | |
EP1699485A4 (en) | ANTI-HYDROLYSATE ANTIBODIES AND ITS USES | |
GB0220214D0 (en) | Compounds and their use | |
IL172510A0 (en) | Antibodies and uses thereof | |
AU2003298129A8 (en) | Floor-furnace chimney and the use thereof | |
EP1589033A4 (en) | ANTIBODY AND ITS USE | |
IL166063A0 (en) | Antibodies and uses thereof | |
AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
GB0227906D0 (en) | Compounds and their use | |
GB0208414D0 (en) | The overlock | |
GB0230134D0 (en) | Compounds and their use | |
EP1627888A4 (en) | ANTIBODY AND ITS USE | |
AU2003216442A8 (en) | Enkurin and uses thereof | |
GB0230281D0 (en) | Compounds and their use | |
GB0218031D0 (en) | Compounds and their use | |
AU2003228397A8 (en) | Hausp-p53 interaction and uses thereof | |
GB0202011D0 (en) | The Fucker | |
GB0220215D0 (en) | Compounds and their use | |
GB0227080D0 (en) | Antibodies and uses thereof | |
GB0215942D0 (en) | Compounds and uses thereof | |
GB0210139D0 (en) | Compounds and uses thereof | |
SI1543010T1 (sl) | N-substituirani hidromorfoni in njihova uporaba |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191105 |